Email this article Role of Drug – Drug Interactions in the Efficacy and Safety of Clarithromycin Treatment for Helicobacter Pylori Eradication
- Authors: Serebrova S.Y.1,2, Kareva E.N.2,3, Eremenko N.N.1,2, Prokof’ev A.B.1,2, Kurguzova D.O.2, Drozdov V.N.2, Lazareva N.B.2, Komissarenko I.A.4, Starodubtsev A.K.2
-
Affiliations:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- I. M. Sechenov First Moscow State Medical University (Sechenov University)
- N. I. Pirogov National Research Medical University
- A. I. Evdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 53, No 8 (2019)
- Pages: 678-679
- Section: Article
- URL: https://journals.rcsi.science/0091-150X/article/view/245941
- DOI: https://doi.org/10.1007/s11094-019-02061-5
- ID: 245941
Cite item
Open Access
Access granted
Subscription Access
Abstract
Current risks from resistance, adverse drug reactions, and drug – drug interactions of clarithromycin used as a component of Helicobacter pylori eradication therapy are reviewed. The acid sensitivity of clarithromycin i responsible for the dependence of its pharmacological properties on the efficacy of proton-pump inhibitors, which could be one reason for the resistance of H. pylori to the macrolide. The potential for clarithromycin drug – drug interactions is related to its metabolism by CYP3A4 and strong inhibition of this enzyme.
About the authors
S. Yu. Serebrova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
E. N. Kareva
I. M. Sechenov First Moscow State Medical University (Sechenov University); N. I. Pirogov National Research Medical University
Author for correspondence.
Email: kareva.en@1msmu.ru
Russian Federation, 8/2 Trubetskaya St., Moscow, 119991; 1 Ostrovityanova St., Moscow, 117997
N. N. Eremenko
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
A. B. Prokof’ev
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
D. O. Kurguzova
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Russian Federation, 8/2 Trubetskaya St., Moscow, 119991
V. N. Drozdov
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Russian Federation, 8/2 Trubetskaya St., Moscow, 119991
N. B. Lazareva
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Russian Federation, 8/2 Trubetskaya St., Moscow, 119991
I. A. Komissarenko
A. I. Evdokimov Moscow State University of Medicine and Dentistry
Email: kareva.en@1msmu.ru
Russian Federation, 20/1 Delegatskaya St., Moscow, 127473
A. K. Starodubtsev
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Russian Federation, 8/2 Trubetskaya St., Moscow, 119991
